NCT06650514View on ClinicalTrials.gov

A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 27, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
OsteosarcomaOsteosarcoma in Children
Interventions
DRUG

OMO-103

OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles).

Trial Locations (1)

08035

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

Sponsors

Collaborators (1)

Peptomyc S.L.
All Listed Sponsors
collaborator

Peptomyc S.L.

INDUSTRY

collaborator

Osteosarcoma Institute

UNKNOWN

collaborator

Curing Kids' Cancer Foundation

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Oregon Health and Science University

OTHER

collaborator

The Morgan Adams Foundation

UNKNOWN

collaborator

The Kristen Ann Carr Fund

UNKNOWN

lead

Vall d'Hebron Institute of Oncology

OTHER

NCT06650514 - A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma | Biotech Hunter | Biotech Hunter